Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Learn how the wash sale rule impacts dividend ETFs in 2024 and what it means for your taxable gains. This quick intro covers key considerations and practical implications for DIY investors.
28,655 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Zevra Therapeutics stock zoomed after a strong earnings release, delivering revenue growth and a first GAAP profit. T...
A firsthand look at NAR's leadership transition reveals a new operating tempo and renewed focus on accountability. Th...
CoreWeave has surged into the AI infrastructure spotlight, but the ride is not risk-free. This article analyzes the g...
A weekend strike by five Long Island Rail Road unions halted service and turned spring travel into a gridlock crisis ...
A fresh stake in COPT Defense Properties signals a calculated tilt toward defense-related real estate. This article b...
A high-net-worth retiree with a $2.1 million 401(K) moves to Nevada to minimize state taxes before his first RMD at 7...
A deadly cattle parasite remains largely uncontained as a key sterile-fly facility won’t be online until late 2027, r...
JPMorgan Chase named Doug Petno and Troy Rohrbaugh as co-presidents, effective immediately, as the board advances its...
July can surprise markets, and Netflix is no exception. This guide breaks down three practical reasons netflix stock ...
Robinhood accelerates its blockchain push to compete with Coinbase, while Base narrows its focus to trading, payments...
OpenAI expands its enterprise push by tying up with four global consultancies to accelerate Frontier AI adoption. The...